All In Biotech

NDA 216018 · Spil

Aspruzyo Sprinkle

Ranolazine · Oral · Anti-anginal

Discontinued

Last checked: Nov 20, 2026Latest source record: Feb 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Feb 28, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

87

17 Phase 3, 3 recruiting

FAERS reports

10,544

9,584 serious, 1,344 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2025.

ASPRUZYO Sprinkle is indicated for the treatment of chronic angina. ASPRUZYO Sprinkle may be used with beta-blockers, nitrates, calcium channel blockers, anti‑platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. ASPRUZYO Sprinkle is an antianginal indicated for the treatment of chronic angina. (1)

Mechanism: The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (I Na ). However, the relationship of this inhibition to angina symptoms is uncertain. The QT prolongation effect of ranolazine on the surface electrocardiogram is the result of inhibition of I Kr which prolongs the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ASPRUZYO SPRINKLE · RANOLAZINE 500MG · GRANULE, EXTENDED RELEASE, ORAL · Discontinued
  • ASPRUZYO SPRINKLE · RANOLAZINE 1GM · GRANULE, EXTENDED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ranolazine" as an intervention, any sponsor and status, largest first.

All 87 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death831
  • myocardial infarction650
  • chest pain622
  • angina pectoris599
  • stent placement582
  • dyspnoea447
  • dizziness438
  • fall387
  • cerebrovascular accident356
  • cardiac disorder311
  • off label use302
  • nausea292

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20062
20077
200815
200923
201033
201161
2012115
2013133
2014548
20151,488
20161,180
20171,382
20181,435
2019984
2020331
2021313
2022370
2023426
2024516
2025674
2026507

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aspruzyo Sprinkle (Ranolazine)

2024 spending

$5K

Beneficiaries

17

21 claims

Per beneficiary

$283

$5.83 per unit

View as table
YearSpending
2020$0
2021$0
2022$26,127
2023$138,947
2024$4,816

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 150 on PubMed

Sponsor: Spil

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.